Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552953 · ClinicalTrials.gov registry record · Phase 1
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02552953 is a Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT02552953, a Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, single arm, dose escalation study in patients with advanced cancers.
Interventions
- DRUG CYC065
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02552953
The ClinicalTrials.gov registry entry for NCT02552953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CYC065 is the first listed.
NCT02552953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02552953 about?
NCT02552953 is a clinical study titled "A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers". This is an open-label, single arm, dose escalation study in patients with advanced cancers.
What is the current status of trial NCT02552953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-09-28. Estimated completion is 2023-08-25.
What interventions are being tested in trial NCT02552953?
The interventions under investigation include: CYC065 (DRUG).
Who is sponsoring clinical trial NCT02552953?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.